AstraZeneca’s Atacand For Congestive Heart Failure To Receive FDA Cmte. Review
This article was originally published in The Pink Sheet Daily
Executive Summary
The agency’s cardio-renal committee will consider three sub-indications for Atacand in the treatment of congestive heart failure. The meeting will be held on Feb. 24.
You may also be interested in...
Atacand Advisory Cmte. To Focus On Concomitant Use With ACE Inhibitors
The focus of FDA's Cardiovascular & Renal Drugs Advisory Committee review of AstraZeneca's Atacand Feb. 24 will be narrowed to a discussion of concomitant use with angiotensin-converting enzyme inhibitors in treating congestive heart failure
Atacand Advisory Cmte. To Focus On Concomitant Use With ACE Inhibitors
The focus of FDA's Cardiovascular & Renal Drugs Advisory Committee review of AstraZeneca's Atacand Feb. 24 will be narrowed to a discussion of concomitant use with angiotensin-converting enzyme inhibitors in treating congestive heart failure
AstraZeneca Submits Atacand For Heart Failure: First ARB To Show Mortality Benefit
Combination use with ACE inhibitors will likely be an issue for the Atacand sNDA; the efficacy seen in AstraZeneca’s CHARM studies conflicts with the Val-HeFT data for Novatis’ angiotensin-II receptor blocker Diovan, which showed no added benefit.